Comparison Between Pre-Planning and Real-Time Planning Techniques in 125I Prostate Brachytherapy by Postimplant Dosimetry, Toxicity and Five-Year Biochemical Outcomes in 665 Patients
この論文をさがす
説明
boost, the whole pelvis was treated to 46 Gy. There were a median of 2 HDR implants with a median dose of 19.5 Gy and a total median prostate dose of 65 Gy. Biochemical failure (BF) was per the Phoenix definition. Clinical failure (CF) was defined as any locoregional recurrence or distant metastasis. Results: Median followup time was 4.4 years for the IGRT group and 7.2 years for the HDR boost group (p ! 0.001). IGRT patients were older, with lower T stage, fewer % cores involved, and less use of neoadjuvant / adjuvant hormone therapy (ADT) (p#0.01 for each). Race, Gleason, pretx PSA, and perineural invasion were similar (pO 0.05). There were 93 BF, 42 CF, and 98 deaths. 3-year and 5-year freedom from BF were 87% and 72% for IGRT vs. 85% and 73% for HDR boost (p 5 0.72). 3-year and 5-year freedom from CF were 97% and 96% for IGRT vs. 90% and 85% for HDR boost (p 5 0.01). 3-year and 5-year OS were 93% and 88% for IGRT vs. 93% and 86% for HDR boost (p 5 0.50).
収録刊行物
-
- Brachytherapy
-
Brachytherapy 10 S29-, 2011-05-01
Elsevier BV